SleepCogni Gets Funding to Help Young People Manage Insomnia
SleepCogni will collaborate with Sheffield Children's NHS Foundation Trust to advance its handheld insomnia devices for use in young patients.
SleepCogni will collaborate with Sheffield Children's NHS Foundation Trust to advance its handheld insomnia devices for use in young patients.
A scientist at IUPUI was awarded a $3 million NIH grant to explore whether treating insomnia can reduce the risk of cardiovascular disease.
Early in my sleep tech career, I figured insomnia was a sleep disorder for the day shift to handle.
Myth or fact?: Cognitive behavioral therapy for insomnia will work only if chronic pain is first addressed.
Read MoreA study led by a University of Missouri School of Medicine researcher has established that CBT-I is an effective first-line treatment for insomnia among individuals with alcohol use disorder, regardless of abstinence from alcohol.
Read MoreHow increased awareness of behavioral sleep medicine could be a game-changer for children.
Read MoreThe Coopérative des techniciens ambulanciers de la Montérégie in Canada is offering its members free access to the services of HALEO, a professional virtual sleep clinic.
Read MoreNox Health has closed the acquisition of Somryst, the only FDA-approved prescription digital therapeutic for adults with chronic insomnia, from Pear Therapeutics.
Read MoreThe digital sleep program, which uses CBT-I-based strategies and text-based coaching, showed meaningful improvements in total sleep time for users in a new study.
Read MoreNox Health Group is set to acquire Pear Therapeutics’ Somryst after being selected as the successful bidder at Pear’s bankruptcy auction last week.
Read MoreTeach patients these relaxation exercises as part of their insomnia therapy.
Read MoreThe COVID-19 pandemic offered researchers a rare opportunity to see the effects of a potentially distressing global event on people with sleep reactivity, that is, those who are vulnerable to stress-related sleep disturbances.
Read MoreJennifer L. Martin, PhD, speaks about the challenges faced by people with insomnia disorder in accessing CBT-I and pharmaceuticals, as well as posits solutions.
Read MoreA paper details a health economic analysis of Somryst, including changes in healthcare resource use, associated costs, and insomnia severity.
Read MoreResMed has acquired Leipzig, Germany-based health tech company mementor; the deal was completed on August 1.
Read MoreInsomnia is linked with anxiety and depression, and a clinical trial evaluates the impact of Somryst on these comorbidities.
Read MoreHundreds of thousands of insomnia patients will be offered digital cognitive behavioral therapy via the app Sleepio instead of sleeping pills.
Read MoreTwo abstracts presented at World Sleep 2022 provide data on Somryst’s efficacy at six months and on its use in older adults.
Read More